Blinatumomab
B-Cell Adult Acute Lymphocytic Leukemia
Explore 23 assets in B-Cell Adult Acute Lymphocytic Leukemia →Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07313852CT.gov A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia | — | Not Yet Recruiting | — | — | — |
NCT07199855CT.gov Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT04044560CT.gov Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant | — | Terminated | — | — | — |
NCT03709719CT.gov Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT03160079CT.gov Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts | — | Completed | — | — | — |
NCT02997761CT.gov Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Adult Acute Lymphocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Blinatumomab (this asset) | Memorial Sloan Kettering Cancer Center | P2 | BB · 67 |
| Vincristine Sulfate | SWOG Cancer Research Network | P3 | BBB |
| Pegaspargase | National Cancer Institute (NCI) | P3 | BBB |
| Dexasone | Mayo Clinic | P3 | BBB |
| Cyclophosphamide | The First Affiliated Hospital of Soochow University | P3 | BBB |
| Cytarabine | Massachusetts General Hospital | P3 | BBB |
| Mercaptopurine Anhydrous | Massachusetts General Hospital | P3 | BBB |
| Adriamycin | Massachusetts General Hospital | P3 | BBB |
| Daunomycin | Children's Oncology Group | P3 | BBB |
+42 more in the B-Cell Adult Acute Lymphocytic Leukemia cohort
Other indications for Blinatumomab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Precursor B-Cell Acute Lymphoblastic Leukemia | — | P3 | BBB · 72 |
| B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2) | — | P3 | BBB · 72 |
| Childhood Acute Lymphoblastic Leukemia | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Blinatumomab in B-Cell Adult Acute Lymphocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/blinatumomab-b-cell-adult-acute-lymphocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →